VCM
TARS icon

Versant Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Versant Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189 Hold
3
– – ﹤0.01% 2731
2026
Q1 		$210 Hold
3
– – ﹤0.01% 2756
2025
Q4 		$246 Hold
3
– – ﹤0.01% 2612
2025
Q3 		$178 Buy
+3
New +$148 ﹤0.01% 2610

Other funds holding TARS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return

Versant Capital Management's TARS Position: Q2 2026 in Review

Versant Capital Management held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 3 shares worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #2731.

Versant Capital Management first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. The position peaked at $246 in Q4 2025. 20 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Versant Capital Management held 3 shares of Tarsus Pharmaceuticals worth $189 as of Q2 2026.
  • Versant Capital Management left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2731 holding.
  • Versant Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Versant Capital Management's Tarsus Pharmaceuticals position peaked at $246 in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.